Early continuous fesoterodine fumarate in a spinal cord transected rat model
Animal study · 33 female Sprague-Dawley rats randomly allocated to six groups: normal controls n=3; untreated injured controls and four injured treatment groups n=6 each. Awake cystometry at six weeks. [1]
One experiment includes both doses, washout groups, cystometry and longitudinal metabolic-cage endpoints. Selected pressure outcomes improved; primary IMP significance was confined to uninterrupted low-dose treatment. Volume endpoints and metabolic-cage measures did not significantly differ from injured controls. No mortality was reported.
| Endpoint | Reported result | Reference |
|---|---|---|
| Intermicturition pressure at six weeks; groups 2, 3, 4, 5 and 6 respectively | mean; median; range (cmH2O) 22.9; 18.6; (15.1–48.5) | 13.4; 11.3; (4.9–26.5) | 12.7; 13.0; (5.4–18.3) | 15.2; 15.2; (12.2–17.9) | 18.1; 19.8; (8.4–22.5) | [1] |
| Maximum pressure versus untreated injured controls | reported significance Groups 3 and 4: p<0.01; group 5: p<0.05; group 6: no significant difference | [1] |
| Threshold pressure versus untreated injured controls | reported significance Groups 3 and 4: p<0.05; groups 5 and 6: no significant difference | [1] |
| Baseline pressure, micturition volume, bladder capacity, residual volume; metabolic-cage micturition volume and frequency | reported comparison No significant differences between treated injured rats and untreated injured controls | [1] |
Conditions shared by the study groups
- Route
- Subcutaneous osmotic pump
- Frequency
- Continuous delivery
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| Group 3: FF 0.18 0.18 mg/kg/day | Group 2: untreated spinal cord transected rats, n=6; group 1: normal rats, n=3, establishes injury-associated changes | IMP not significantly reduced; Pmax p<0.01 and Pthres p<0.05 versus group 2. Baseline pressure and cystometric volume endpoints were not significantly different from group 2. | [1] |
| Group 4: FF 0.12 0.12 mg/kg/day | Group 2: untreated spinal cord transected rats, n=6; group 1: normal rats, n=3, establishes injury-associated changes | IMP p<0.05, Pmax p<0.01 and Pthres p<0.05 versus group 2. Baseline pressure and cystometric volume endpoints were not significantly different from group 2. | [1] |
| Group 5: FF 0.18 plus 72-h washout 0.18 mg/kg/day | Group 2: untreated spinal cord transected rats, n=6; group 1: normal rats, n=3, establishes injury-associated changes | Pmax p<0.05; IMP and Pthres not significantly reduced versus group 2. Baseline pressure and cystometric volume endpoints were not significantly different from group 2. | [1] |
| Group 6: FF 0.12 plus 72-h washout 0.12 mg/kg/day | Group 2: untreated spinal cord transected rats, n=6; group 1: normal rats, n=3, establishes injury-associated changes | IMP, Pmax and Pthres not significantly reduced versus group 2. Baseline pressure and cystometric volume endpoints were not significantly different from group 2. | [1] |
- Group 3: FF 0.18
- Model: Female Sprague-Dawley rats, 350–400 g, spinal cord transection at T10; n=6 per group
- Treatment course: Started at transection; continuous through six-week cystometry
- Reported limits: Vehicle composition, analytical purity, lot and separate stereochemical verification are not reported in the acquired article. Injured controls were untreated; no vehicle-pump control is described.
- Group 4: FF 0.12
- Model: Female Sprague-Dawley rats, 350–400 g, spinal cord transection at T10; n=6 per group
- Treatment course: Started at transection; continuous through six-week cystometry
- Reported limits: Vehicle composition, analytical purity, lot and separate stereochemical verification are not reported in the acquired article. Injured controls were untreated; no vehicle-pump control is described.
- Group 5: FF 0.18 plus 72-h washout
- Model: Female Sprague-Dawley rats, 350–400 g, spinal cord transection at T10; n=6 per group
- Treatment course: Started at transection; pump removed 72 h before six-week cystometry
- Reported limits: Vehicle composition, analytical purity, lot and separate stereochemical verification are not reported in the acquired article. Injured controls were untreated; no vehicle-pump control is described.
- Group 6: FF 0.12 plus 72-h washout
- Model: Female Sprague-Dawley rats, 350–400 g, spinal cord transection at T10; n=6 per group
- Treatment course: Started at transection; pump removed 72 h before six-week cystometry
- Reported limits: Vehicle composition, analytical purity, lot and separate stereochemical verification are not reported in the acquired article. Injured controls were untreated; no vehicle-pump control is described.
Methods and source locations
Compound reported in the paper: Fesoterodine fumarate; Compound label in the paper: FF
Reported fumarate treatment in this rat model only; no conversion to free-base doses, supplier validation, human efficacy, durable prevention or molecular remodeling claim.
Materials and Methods: Study design, Experimental animals, Osmotic pump implantation/removal, Cystometry, Statistical analysis; Results; Table 2; Figures 3–5
Intermicturition pressure at six weeks; groups 2, 3, 4, 5 and 6 respectively: Awake cystometry; n=6 rats per injured group. Only group 4 differs significantly from group 2 (p<0.05), post-hoc Dunn’s test for Kruskal-Wallis analysis. Means, medians and ranges are distinct, not ± errors. — Table 2, IMP row and footnote; Figure 3 axis; Methods: Cystometry, Study design, Statistical analysis
Maximum pressure versus untreated injured controls: Post-hoc Dunn’s test for Kruskal-Wallis analysis; n=6 rats per injured group. — Table 2, Pmax row and footnote; Results: Maximum pressure; Figure 4
Threshold pressure versus untreated injured controls: Post-hoc Dunn’s test for Kruskal-Wallis analysis; n=6 rats per injured group. — Table 2, Pthres row and footnote; Results: Threshold pressure; Figure 5
Baseline pressure, micturition volume, bladder capacity, residual volume; metabolic-cage micturition volume and frequency: Cystometry at six weeks; metabolic-cage recordings for 6 h once weekly during weeks 3–5. No claim of equivalence. — Table 2, Pbase/MV/BC/RV rows; Results: Other cystometric parameters; Metabolic cage parameters; Methods: Metabolic cage recording
Group 3: FF 0.18 · Methods: Study design; Experimental animals; Osmotic pump implantation/removal; Results; Table 2 and footnote
Group 4: FF 0.12 · Methods: Study design; Experimental animals; Osmotic pump implantation/removal; Results; Table 2 and footnote
Group 5: FF 0.18 plus 72-h washout · Methods: Study design; Experimental animals; Osmotic pump implantation/removal; Results; Table 2 and footnote
Group 6: FF 0.12 plus 72-h washout · Methods: Study design; Experimental animals; Osmotic pump implantation/removal; Results; Table 2 and footnote